Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 15 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2025 Filed Feb 21, 2025 21:47 UTC |
Barlow CarroleeDirector
|
GrantRestricted Stock Unit · Derivative | 4,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007179 · wk-form4_1740174429.xml · derivative · entry 3 Barlow Carrolee · CIK 0001745316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,475 Underlying: Common Stock · 4,475 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:47 UTC |
Barlow CarroleeDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 7,296 | $0.00 Strike: $33.52 | $0.00 |
DisclosureSEC source: 0001628280-25-007179 · wk-form4_1740174429.xml · derivative · entry 2 Barlow Carrolee · CIK 0001745316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,296 Underlying: Common Stock · 7,296 shares Expires 2035-02-19 F1 · derivative.exercise_date: The option vests on February 19, 2026. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:45 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
GrantRestricted Stock Unit · Derivative | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007170 · wk-form4_1740174332.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026. F3 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:45 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $33.52 | $0.00 |
DisclosureSEC source: 0001628280-25-007170 · wk-form4_1740174332.xml · derivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-02-19 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 19, 2026. Read SEC document |
| February 17, 2025 Filed Feb 19, 2025 21:35 UTC |
Mottola FrankSVP, Quality, GMP, Ops, IT
|
GrantPerformance Share Units · Derivative | 2,625 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-006401 · wk-form4_1740000906.xml · derivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,625 Underlying: Common Stock · 2,625 shares Expires not disclosed F1 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F1 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| February 17, 2025 Filed Feb 19, 2025 21:54 UTC |
Khattar Jack A.Director · President, CEO
|
GrantPerformance Share Units · Derivative | 38,640 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-006420 · wk-form4_1740002035.xml · derivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,640 Underlying: Common Stock · 38,640 shares Expires not disclosed F1 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F1 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| February 05, 2025 Filed Feb 6, 2025 21:57 UTC |
Mottola FrankSVP, Quality, GMP, Ops, IT
|
GrantPerformance Share Units · Derivative | 2,010 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-004278 · wk-form4_1738879018.xml · derivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,010 Underlying: Common Stock · 2,010 shares Expires not disclosed F2 · derivative.exercise_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units, portions of which vested upon the achievement of individual performance objectives within defined performance periods, which objectives were established on May 3, 2022. F2 · derivative.expiration_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units, portions of which vested upon the achievement of individual performance objectives within defined performance periods, which objectives were established on May 3, 2022. Read SEC document |
| February 05, 2025 Filed Feb 6, 2025 21:57 UTC |
Mottola FrankSVP, Quality, GMP, Ops, IT
|
GrantPerformance Share Units · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-004278 · wk-form4_1738879018.xml · derivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F1 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F1 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 21:37 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 9,477 | $0.00 Strike: $29.61 | $0.00 |
DisclosureSEC source: 0001628280-25-004073 · wk-form4_1738791425.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,250 Underlying: Common Stock · 9,477 shares Expires 2031-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested in four equal installments beginning on February 19, 2022. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 21:37 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
SaleCommon Stock | 9,477 | $39.70 | $376,236.90 |
DisclosureSEC source: 0001628280-25-004073 · wk-form4_1738791425.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,149 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.61 to $39.90. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 21:37 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionCommon Stock | 9,477 | $29.61 | $280,613.97 |
DisclosureSEC source: 0001628280-25-004073 · wk-form4_1738791425.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,626 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 22:01 UTC |
Rubin JonathanSVP, Chief Medical Officer
|
GrantPerformance Share Units · Derivative | 1,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-003016 · wk-form4_1738188071.xml · derivative · entry 2 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 1,875 shares Expires not disclosed F2 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F2 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 21:59 UTC |
Mottola FrankSVP, Quality, GMP, Ops, IT
|
GrantPerformance Share Units · Derivative | 1,125 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-003012 · wk-form4_1738187944.xml · derivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,125 Underlying: Common Stock · 1,125 shares Expires not disclosed F2 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F2 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 22:04 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 700 | $0.00 Strike: $29.61 | $0.00 |
DisclosureSEC source: 0001628280-25-003018 · wk-form4_1738188277.xml · derivative · entry 7 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,477 Underlying: Common Stock · 700 shares Expires 2031-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in four equal installments beginning on February 19, 2022. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 22:04 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
GrantPerformance Share Units · Derivative | 1,650 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-003018 · wk-form4_1738188277.xml · derivative · entry 6 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,650 Underlying: Common Stock · 1,650 shares Expires not disclosed F5 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F5 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 22:04 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
SaleCommon Stock | 700 | $39.62 | $27,734.00 |
DisclosureSEC source: 0001628280-25-003018 · wk-form4_1738188277.xml · nonDerivative · entry 4 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,149 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.61 to $39.63. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 22:04 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionCommon Stock | 700 | $29.61 | $20,727.00 |
DisclosureSEC source: 0001628280-25-003018 · wk-form4_1738188277.xml · nonDerivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2025 Filed Feb 5, 2025 21:33 UTC Amendment |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 700 | $0.00 Strike: $29.61 | $0.00 |
DisclosureSEC source: 0001628280-25-004067 · wk-form4a_1738791207.xml · derivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,727 Underlying: Common Stock · 700 shares Expires 2031-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested in four equal installments beginning on February 19, 2022. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 22:04 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,573 | $0.00 Strike: $29.61 | $0.00 |
DisclosureSEC source: 0001628280-25-003018 · wk-form4_1738188277.xml · derivative · entry 5 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,177 Underlying: Common Stock · 2,573 shares Expires 2031-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in four equal installments beginning on February 19, 2022. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 22:04 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
SaleCommon Stock | 2,573 | $39.62 | $101,942.26 |
DisclosureSEC source: 0001628280-25-003018 · wk-form4_1738188277.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,149 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.61 to $39.67. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 22:04 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionCommon Stock | 2,573 | $29.61 | $76,186.53 |
DisclosureSEC source: 0001628280-25-003018 · wk-form4_1738188277.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 470 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 22, 2025 Filed Jan 23, 2025 16:33 UTC |
Hudson Frederick M.Director
|
Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001628280-25-002388 · wk-form4_1737668026.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2025 Filed Jan 23, 2025 16:33 UTC |
Hudson Frederick M.Director
|
Exercise / conversionCommon Stock | 20,000 | $9.13 | $182,600.00 |
DisclosureSEC source: 0001628280-25-002388 · wk-form4_1737668026.xml · nonDerivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2024 Filed Dec 30, 2024 21:13 UTC |
Rubin JonathanSVP, Chief Medical Officer
|
Exercise / conversionPerformance Share Unit · Derivative | 1,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-052575 · wk-form4_1735593186.xml · derivative · entry 6 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F6 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| December 27, 2024 Filed Dec 30, 2024 21:13 UTC |
Rubin JonathanSVP, Chief Medical Officer
|
Exercise / conversionPerformance Share Unit · Derivative | 750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-052575 · wk-form4_1735593186.xml · derivative · entry 5 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023 and modified on December 12, 2024. F5 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023 and modified on December 12, 2024. Read SEC document |
| December 27, 2024 Filed Dec 30, 2024 21:13 UTC |
Rubin JonathanSVP, Chief Medical Officer
|
Tax withholdingCommon Stock | 821 | $35.59 | $29,219.39 |
DisclosureSEC source: 0001628280-24-052575 · wk-form4_1735593186.xml · nonDerivative · entry 4 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,595 F3 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| December 27, 2024 Filed Dec 30, 2024 21:13 UTC |
Rubin JonathanSVP, Chief Medical Officer
|
Exercise / conversionCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-052575 · wk-form4_1735593186.xml · nonDerivative · entry 3 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2024. Read SEC document |
| December 27, 2024 Filed Dec 30, 2024 21:13 UTC |
Rubin JonathanSVP, Chief Medical Officer
|
Tax withholdingCommon Stock | 281 | $35.59 | $10,000.79 |
DisclosureSEC source: 0001628280-24-052575 · wk-form4_1735593186.xml · nonDerivative · entry 2 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,541 F3 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| December 27, 2024 Filed Dec 30, 2024 21:13 UTC |
Rubin JonathanSVP, Chief Medical Officer
|
Exercise / conversionCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-052575 · wk-form4_1735593186.xml · nonDerivative · entry 1 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023. F2 · balance_after: Includes an aggregate of 431 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| December 27, 2024 Filed Dec 30, 2024 21:08 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionPerformance Share Unit · Derivative | 14,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-052573 · wk-form4_1735592879.xml · derivative · entry 7 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023 and modified on December 12, 2024. F5 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023 and modified on December 12, 2024. Read SEC document |
| December 27, 2024 Filed Dec 30, 2024 21:08 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionPerformance Share Unit · Derivative | 38,640 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-052573 · wk-form4_1735592879.xml · derivative · entry 6 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,640 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F4 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| December 27, 2024 Filed Dec 30, 2024 21:08 UTC |
Khattar Jack A.Director · President, CEO
|
Tax withholdingCommon Stock | 6,666 | $35.59 | $237,242.94 |
DisclosureSEC source: 0001628280-24-052573 · wk-form4_1735592879.xml · nonDerivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 953,579 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| December 27, 2024 Filed Dec 30, 2024 21:08 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-052573 · wk-form4_1735592879.xml · nonDerivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 960,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023. Read SEC document |
| December 27, 2024 Filed Dec 30, 2024 21:08 UTC |
Khattar Jack A.Director · President, CEO
|
Tax withholdingCommon Stock | 18,567 | $35.59 | $660,799.53 |
DisclosureSEC source: 0001628280-24-052573 · wk-form4_1735592879.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 946,245 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| December 27, 2024 Filed Dec 30, 2024 21:08 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionCommon Stock | 38,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-052573 · wk-form4_1735592879.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 964,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2024. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 13:31 UTC |
Rubin JonathanSVP, Chief Medical Officer
|
GrantPerformance Share Unit · Derivative | 1,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-052395 · wk-form4_1735219861.xml · derivative · entry 2 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 1,875 shares Expires not disclosed F2 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F2 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 13:31 UTC |
Rubin JonathanSVP, Chief Medical Officer
|
GrantPerformance Share Unit · Derivative | 750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-052395 · wk-form4_1735219861.xml · derivative · entry 1 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750 Underlying: Common Stock · 750 shares Expires not disclosed F1 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023 and modified on December 12, 2024. F1 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023 and modified on December 12, 2024. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 13:42 UTC |
Khattar Jack A.Director · President, CEO
|
GrantPerformance Share Unit · Derivative | 38,640 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-052397 · wk-form4_1735220518.xml · derivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,640 Underlying: Common Stock · 38,640 shares Expires not disclosed F2 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F2 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 13:42 UTC |
Khattar Jack A.Director · President, CEO
|
GrantPerformance Share Unit · Derivative | 14,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-052397 · wk-form4_1735220518.xml · derivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires not disclosed F1 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023 and modified on December 12, 2024. F1 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023 and modified on December 12, 2024. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 21:36 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 12,745 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001628280-24-049934 · wk-form4_1733348181.xml · derivative · entry 6 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,745 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 24, 2018. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 21:36 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 8,750 | $0.00 Strike: $23.99 | $0.00 |
DisclosureSEC source: 0001628280-24-049934 · wk-form4_1733348181.xml · derivative · entry 5 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires 2030-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 21, 2021. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 21:36 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
SaleCommon Stock | 12,745 | $36.68 | $467,486.60 |
DisclosureSEC source: 0001628280-24-049934 · wk-form4_1733348181.xml · nonDerivative · entry 4 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,679 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.24 to $37.00. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 21:36 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionCommon Stock | 12,745 | $25.30 | $322,448.50 |
DisclosureSEC source: 0001628280-24-049934 · wk-form4_1733348181.xml · nonDerivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 21:36 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
SaleCommon Stock | 8,750 | $36.68 | $320,950.00 |
DisclosureSEC source: 0001628280-24-049934 · wk-form4_1733348181.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,679 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.29 to $37.01. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 21:36 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionCommon Stock | 8,750 | $23.99 | $209,912.50 |
DisclosureSEC source: 0001628280-24-049934 · wk-form4_1733348181.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 16:15 UTC |
NEWHALL CHARLES W IIIDirector
|
Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001628280-24-047155 · wk-form4_1731446109.xml · derivative · entry 3 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 16:15 UTC |
NEWHALL CHARLES W IIIDirector
|
SaleCommon Stock | 10,700 | $36.24 | $387,768.00 |
DisclosureSEC source: 0001628280-24-047155 · wk-form4_1731446109.xml · nonDerivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,275 F1 · shares: The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 3, 2025 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.02 to $36.46. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 16:15 UTC |
NEWHALL CHARLES W IIIDirector
|
Exercise / conversionCommon Stock | 20,000 | $9.13 | $182,600.00 |
DisclosureSEC source: 0001628280-24-047155 · wk-form4_1731446109.xml · nonDerivative · entry 1 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 16:14 UTC |
Hudson Frederick M.Director
|
SaleCommon Stock | 8,722 | $36.28 | $316,434.16 |
DisclosureSEC source: 0001628280-24-047152 · wk-form4_1731446048.xml · nonDerivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,395 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.25 to $36.31. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 21:13 UTC |
GEMAYEL GEORGESDirector
|
Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 10,787 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001628280-24-047145 · wk-form4_1731445977.xml · derivative · entry 3 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,787 shares Expires 2025-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.